How the FDA Regulates Peptides: Full Framework

Peptide Regulation

80+ FDA-Approved Peptide Drugs

More than 80 peptide-based drugs have received FDA approval, from insulin to semaglutide. But the vast majority of peptides used in clinical practice exist in a regulatory gray zone between approved drugs and unregulated research chemicals.

FDA Bulk Drug Substances Guidance, 2024

FDA Bulk Drug Substances Guidance, 2024

View as image

The FDA does not regulate "peptides" as a single category. Peptides enter the regulatory system through at least four distinct pathways: as approved drugs (through New Drug Applications), as compounded medications (through 503A or 503B pharmacy frameworks), as dietary supplements (if derived from food sources), or as unregulated research chemicals (sold "for research use only"). Each pathway carries different requirements for safety, efficacy, and manufacturing quality. For the underlying legal framework that governs compounding, see the 503A bulk drug substances list.

Pathway 1: FDA-Approved Peptide Drugs

The gold standard. An FDA-approved peptide drug has completed preclinical testing, Phase I/II/III clinical trials, and a New Drug Application (NDA) or Biologics License Application (BLA) review. The manufacturer must demonstrate safety, efficacy, and manufacturing consistency.

Examples span nearly every therapeutic area:

• Diabetes/obesity: insulin, semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda), exenatide (Byetta)
• Osteoporosis: teriparatide (Forteo), abaloparatide (Tymlos)
• HIV: enfuvirtide (Fuzeon)
• Cancer: lutetium-177 dotatate (Lutathera), octreotide (Sandostatin)
• Rare diseases: afamelanotide (Scenesse), tesamorelin (Egrifta), setmelanotide (Imcivree)

These drugs undergo post-market surveillance, carry FDA-approved labeling with defined indications, dosing, and warnings, and are manufactured under current Good Manufacturing Practice (cGMP) requirements. The approval process typically costs $1-2 billion and takes 10-15 years from discovery to market.

The regulatory challenge: many peptides studied in research have not and may never complete this process. The cost is prohibitive for peptides with small potential patient populations, off-patent molecules, or those with primarily preclinical (animal) evidence. A peptide like BPC-157, which has extensive animal data but no completed human trials, faces an unfavorable economics-to-evidence ratio: the research base is insufficient for NDA approval, but the commercial incentive to fund $1+ billion in clinical trials does not exist for an unpatentable molecule.

The peptide drug approval landscape has accelerated in recent years. Between 2015 and 2025, FDA approved more peptide drugs than in the previous two decades combined, driven largely by GLP-1 receptor agonists for diabetes and obesity. This acceleration demonstrates that the regulatory pathway works for peptides with strong commercial backing and clear therapeutic targets, but leaves the majority of peptides in the research literature without a viable path to approval.

Pathway 2: Compounding Under 503A

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound medications for individual patients based on a valid prescription from a licensed prescriber. This is the pathway through which most non-approved peptides reach patients legally.

What 503A Allows

A 503A pharmacy can compound a peptide medication if:

• A licensed prescriber writes a patient-specific prescription
• The bulk drug substance (the raw peptide) meets quality standards
• The substance is listed on the FDA's 503A bulks list or is the active ingredient in an approved drug or has a USP monograph
• The compounded product is not "essentially a copy" of a commercially available drug

What 503A Does Not Require

Unlike FDA-approved drugs, 503A compounded peptides do not require clinical trials demonstrating efficacy, do not carry FDA-approved labeling, and are not subject to FDA pre-market review. The pharmacy must follow state pharmacy board regulations and USP standards for sterile compounding (USP <797>), but these requirements focus on manufacturing quality, not therapeutic efficacy.

For a detailed comparison of the two compounding frameworks, see 503A vs 503B compounding. For quality standards, see how compounding pharmacies make peptides.

Pathway 3: Compounding Under 503B

Section 503B created "outsourcing facilities" that can compound medications without patient-specific prescriptions, allowing them to supply physician offices, clinics, and hospitals with ready-made preparations. These facilities face more stringent oversight than 503A pharmacies:

• Must register with the FDA
• Subject to FDA inspection under cGMP standards
• Must report adverse events to the FDA
• Can only compound substances on the 503B bulks list

The 503B pathway was created after the 2012 New England Compounding Center meningitis outbreak that killed 64 people, highlighting the need for federal oversight of large-scale compounding operations. 503B facilities occupy a middle ground between traditional compounding pharmacies and pharmaceutical manufacturers.

The Category Classification System

The FDA classifies bulk drug substances nominated for compounding use into three categories:

Category 1: May Be Compounded

Substances where the FDA has determined there is no significant safety concern for compounding use. 503A and 503B pharmacies may use these substances. Category 1 includes well-characterized peptides with established safety profiles, even if they lack FDA approval as standalone drugs.

Category 2: Safety Concerns

Substances the FDA has determined present significant safety risks when used in compounding. Pharmacies may not compound with Category 2 substances. The FDA bases this determination on factors including: known adverse effects, narrow therapeutic index, complexity of the molecule, potential for harm from improper preparation, and lack of adequate characterization data.

Category 3: Insufficient Data

Substances where the FDA has insufficient information to make a Category 1 or 2 determination. These remain in regulatory limbo until additional data is submitted and reviewed.

For a detailed analysis of how this classification works, see FDA Category 1 vs Category 2 peptides.

The 2023-2024 Category 2 Reclassification

Between late 2023 and December 2024, the FDA moved 19 widely used peptides from Category 1 to Category 2. This effectively prohibited licensed compounding pharmacies from preparing these substances for patient use. The affected peptides included:

• BPC-157 (body protection compound): widely used for injury recovery
• Thymosin alpha 1: immune modulation
• Thymosin beta 4 / TB-500: tissue repair
• CJC-1295: growth hormone releasing
• Ipamorelin: growth hormone secretagogue
• AOD-9604: fat metabolism fragment
• DSIP: sleep peptide
• Selank: anxiolytic
• Semax: nootropic
• KPV: anti-inflammatory tripeptide
• Melanotan II: melanogenesis
• PT-141 (bremelanotide): sexual function (though an FDA-approved version, Vyleesi, exists)

The FDA cited insufficient safety data, lack of adequate characterization, and potential for harm from uncontrolled use. The decision was controversial because many of these peptides had been compounded and prescribed for years under 503A. For the BPC-157 classification specifically, see BPC-157 and the FDA. For the full timeline, see the timeline of FDA peptide restrictions.

The 2026 Reversal

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on Category 2 would be moved back to Category 1 status. This decision allows licensed compounding pharmacies to legally prepare these peptides again. The reversal reflected a policy shift prioritizing patient access over the precautionary approach that drove the original reclassification.

The remaining peptides that were not returned to Category 1 included substances where the safety concerns were considered more substantial or where the characterization data remained insufficient. The Pharmacy Compounding Advisory Committee (PCAC) was scheduled to review additional peptides for potential reclassification.

Pathway 4: Gray Market Research Chemicals

Outside the regulated pathways, peptides are widely sold online as "research chemicals" labeled "for research use only" or "not for human consumption." These products:

• Are not subject to FDA oversight
• Have no manufacturing quality requirements
• May contain impurities, incorrect dosing, or degraded material
• Cannot legally be sold for human use but are purchased by individuals for self-administration

Hach et al. (2024) investigated the impact of manufacturing processes on the quality of follow-on GLP-1 preparations, finding significant differences in properties and quality compared to reference products. This quality gap is far wider for unregulated gray market peptides, where no quality comparison to any reference standard is required.^[1]

The gray market exists because demand for peptides exceeds the supply available through regulated channels. When the FDA moved peptides to Category 2, the regulated compounding supply disappeared, but demand did not. This pushed more consumers toward unregulated sources. For a deeper analysis, see for research use only: the legal fiction of gray market peptides.

GLP-1 Compounding: A Special Case

Semaglutide and tirzepatide present a unique regulatory situation. Both are FDA-approved drugs that experienced severe supply shortages from 2023-2025 due to unprecedented demand. Under the Drug Quality and Security Act, compounding pharmacies can compound copies of drugs that are on the FDA drug shortage list.

During the shortage period, 503A and 503B pharmacies compounded semaglutide and tirzepatide at a fraction of brand-name cost. When supply began to stabilize in late 2025, the FDA moved to wind down compounding policies, requiring pharmacies to transition away from compounding these drugs as brand-name supply became adequate.

This created a legal and practical conflict: patients who had been receiving compounded GLP-1 agonists at $200-400/month faced returning to brand-name drugs at $1,000-1,500/month. The regulatory framework was designed to protect patients from unsafe compounding, but the economic consequences of enforcing it against compounded GLP-1s generated significant public and political pushback.

How This Framework Affects Research and Patients

The regulatory framework creates a three-tier system of peptide access:

Tier 1: FDA-approved drugs. Highest evidence quality, highest cost, limited selection (approximately 80 peptides out of thousands studied).

Tier 2: Compounded peptides. Moderate quality assurance (pharmacy board oversight, USP standards), moderate cost, broader selection (limited by the category system).

Tier 3: Gray market research chemicals. No quality assurance, lowest cost, broadest selection (any peptide that can be synthesized).

Patients and practitioners navigate this framework based on availability, cost, regulatory status, and risk tolerance. The 2023-2024 Category 2 reclassification compressed Tier 2 by removing popular peptides from compounding access, while the 2026 reversal partially reopened it. The ongoing regulatory evolution means the specific peptides available through each tier continues to change.

Limitations

This overview reflects the regulatory landscape as of March 2026. FDA policy on peptide compounding has changed multiple times in recent years and will continue to evolve. Specific category assignments should be verified against the current FDA bulks lists before making prescribing or compounding decisions.

State pharmacy board regulations add another layer of complexity that varies by jurisdiction. Some states have additional restrictions on peptide compounding beyond federal requirements; others have been more permissive.

The evidence base for many compounded peptides remains preclinical (animal studies only). The FDA's category system attempts to balance access with safety, but the data available for many peptides is insufficient for definitive safety determinations in either direction.

International regulatory approaches vary widely. Cerebrolysin is approved for clinical use in over 50 countries but not in the United States. BPC-157 is available through licensed clinics in some jurisdictions while being restricted in others. Selank and Semax are approved in Russia but have no regulatory status in Western countries. These discrepancies create a global patchwork where the legal status of any given peptide depends entirely on the jurisdiction, not on the evidence base. Patients who travel or purchase peptides internationally may encounter substances that are legal in one country and banned in another, with the same molecule and the same evidence behind it.

The Bottom Line

The FDA regulates peptides through four pathways: approved drugs (NDA/BLA), 503A compounding (patient-specific prescriptions), 503B outsourcing facilities, and by default the unregulated gray market that exists outside these frameworks. The category classification system (1, 2, 3) determines which bulk drug substances may be compounded. The 2023-2024 reclassification of 19 peptides to Category 2 disrupted patient access. The partial 2026 reversal restored most of them to Category 1. The regulatory landscape continues to shift as the FDA balances patient access, safety concerns, and political pressure.

Frequently Asked Questions

How does the FDA regulate peptides?

The FDA regulates peptides through multiple pathways. Approved peptide drugs (semaglutide, teriparatide, enfuvirtide) go through the standard NDA/BLA process. Compounded peptides are regulated through 503A (patient-specific) or 503B (outsourcing facility) frameworks. The FDA's category system classifies bulk drug substances as Category 1 (may compound), Category 2 (safety concerns), or Category 3 (insufficient data).

What peptides did the FDA ban in 2024?

In 2023-2024, the FDA moved 19 peptides from Category 1 to Category 2, effectively prohibiting their compounding. These included BPC-157, thymosin alpha 1, thymosin beta 4, CJC-1295, ipamorelin, AOD-9604, DSIP, Selank, Semax, KPV, and melanotan II. In February 2026, approximately 14 of these were moved back to Category 1.

What is the difference between 503A and 503B pharmacies?

503A pharmacies compound patient-specific medications based on individual prescriptions and are primarily regulated by state pharmacy boards. 503B outsourcing facilities can compound without patient-specific prescriptions (for office stock), must register with the FDA, are subject to FDA inspection, and must report adverse events. 503B faces stricter federal oversight.

Are research peptides legal?

Peptides sold as "research chemicals" or "for research use only" exist outside FDA regulation. They are technically legal to sell for laboratory research but cannot legally be sold for human consumption. No manufacturing quality standards apply. Individuals who purchase and self-administer these products operate in a legal gray area with no consumer protections.

Why were peptides moved to Category 2?

The FDA cited insufficient safety data, lack of adequate molecular characterization, and potential for harm from uncontrolled compounding use. Many affected peptides had only animal study data supporting their use in humans, and the FDA determined that the risk-benefit profile did not support continued compounding access without more rigorous evaluation.

Can a doctor still prescribe compounded peptides?

Yes, for peptides classified as Category 1. A licensed prescriber can write a prescription for a Category 1 peptide, and a licensed 503A pharmacy can compound it for the specific patient. Category 2 peptides cannot be legally compounded regardless of whether a prescription exists. The specific peptides in each category change as the FDA updates its bulks lists.